Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...155156157158159160161162163164165...208209»
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Trial completion date, Trial primary completion date:  IRENE: Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (clinicaltrials.gov) -  Apr 22, 2021   
    P=N/A,  N=400, Recruiting, 
    Initiation date: Jan 2021 --> Apr 2021 Trial completion date: Sep 2021 --> Apr 2022 | Trial primary completion date: Sep 2021 --> Apr 2022
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
    Enrollment closed, Trial completion date:  Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers (clinicaltrials.gov) -  Apr 22, 2021   
    P1,  N=6, Active, not recruiting, 
    N=32 --> 82 | Trial completion date: Nov 2020 --> Dec 2022 | Trial primary completion date: Jun 2020 --> Dec 2020 Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2021
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma
    Enrollment closed, Enrollment change, Trial completion date:  Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer (clinicaltrials.gov) -  Apr 22, 2021   
    P1,  N=20, Active, not recruiting, 
    Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2021 Recruiting --> Active, not recruiting | N=120 --> 20 | Trial completion date: Dec 2020 --> Dec 2021
  • ||||||||||  SHR-1703 / Jiangsu Hengrui Pharma
    New P1 trial:  A Trial of SHR-1703 in Healthy Subjects (clinicaltrials.gov) -  Apr 22, 2021   
    P1,  N=48, Not yet recruiting, 
  • ||||||||||  Preclinical, Journal:  Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing. (Pubmed Central) -  Apr 20, 2021   
    To that end, using three bacteria-based assays, we screened a library of 2839 approved-for-human-use drugs and identified the following potential channel-blockers: Capreomycin, Pentamidine, Spectinomycin, Kasugamycin, Plerixafor, Flumatinib, Litronesib, Darapladib, Floxuridine and Fludarabine. The stage is now set for examining the activity of these compounds in detailed electrophysiological studies and their impact on the whole virus with appropriate biosafety measures.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open:  Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer (clinicaltrials.gov) -  Apr 20, 2021   
    P2,  N=60, Recruiting, 
    The stage is now set for examining the activity of these compounds in detailed electrophysiological studies and their impact on the whole virus with appropriate biosafety measures. Not yet recruiting --> Recruiting
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Enrollment open, Trial initiation date:  A Study of SHR-1210 (clinicaltrials.gov) -  Apr 12, 2021   
    P2,  N=250, Recruiting, 
    Preliminary evidence of clinical activity was observed, which warrants further validation. Not yet recruiting --> Recruiting | Initiation date: Jan 2021 --> Apr 2021
  • ||||||||||  Review, Journal:  Enriching Cancer Pharmacology with Drugs of Marine Origin. (Pubmed Central) -  Apr 10, 2021   
    In this scenario, innovation from marine-based pharmaceuticals has helped advance cancer chemotherapy in many aspects, as most of these are designated as first-in-class drugs. Herein, by examining the path from discovery to development of clinically approved drugs of marine origin for cancer treatment - cyrabine (Cytosar-U®), trabectedin (Yondelis®), eribulin (Halaven®), brentuximab vedotin (Adcetris®) and plitidepsin (Aplidin®) - plus those in late clinical trial phases - lurbinectedin, plinabulin, marizomib and plocabulin -, the present review offers a critical analysis of the contributions given by these new compounds to cancer pharmacotherapy.
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    Trial completion:  AMBER2: A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis. (clinicaltrials.gov) -  Apr 8, 2021   
    P2,  N=164, Completed, 
    Thus, specific blockage of circRACGAP1 may be a potential therapeutic strategy to reduce the toxicities of apatinib and enhance its therapeutic effect in human GC. Active, not recruiting --> Completed
  • ||||||||||  edralbrutinib (TG-1701) / TG Therap
    Enrollment open:  An Open Label Study of the Effects of SHR1459 in NMOSDs Patients (clinicaltrials.gov) -  Apr 8, 2021   
    P2,  N=10, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Clinical, Journal:  Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer: A case report. (Pubmed Central) -  Apr 7, 2021   
    Apatinib has a certain clinical effect as the maintenance treatment for advanced oesophageal squamous cell carcinoma patients, with mild adverse reactions and high safety. Preoperative short term targeted treatment with apatinib for locally advanced inoperable DTC may become a promising neoadjuvant therapy that, can reduce the tumor size and decrease stage, thus making the complete and safe removal of the lesion feasible.
  • ||||||||||  AiRuiKa (camrelizumab) / Incyte, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Clinical, Journal, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker:  Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient: A case report. (Pubmed Central) -  Apr 7, 2021   
    Preoperative short term targeted treatment with apatinib for locally advanced inoperable DTC may become a promising neoadjuvant therapy that, can reduce the tumor size and decrease stage, thus making the complete and safe removal of the lesion feasible. This case described here demonstrated that immunotherapy of PD-1 inhibitor is a promising treatment option for refractory MFS with PD-L1 positive or tumor mutational burden -high, which could contribute to effective tumor response.
  • ||||||||||  SHR2285 / Jiangsu Hengrui Pharma
    New P1 trial:  A Trial of SHR2285 in Healthy Subjects (clinicaltrials.gov) -  Apr 1, 2021   
    P1,  N=36, Not yet recruiting,